ANDA 87065, held by Lyphomed. Dexamethasone Sodium Phosphate.
As of Nov 21, 2026, ANDA 87065 (Dexamethasone Sodium Phosphate), held by Lyphomed, was first approved by FDA on May 29, 1981, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 29, 1981 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dexamethasone Sodium PhosphateEQ 4MG PHOSPHATE/ML · injectable;injection | Dexamethasone Sodium Phosphate | Discontinued |
| Jul 31, 1991 | Supplement 21Labeling | Approved | None posted |
| Feb 2, 1989 | Supplement 15Labeling | Approved | None posted |
| May 29, 1981 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters